Oxford Biomedica growth targets, business update

 

• Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing)
• On track to achieve 2023 guidanceprovided at the Interim Results and reiteration of medium term guidance; growth supported by new orders recently signed across lentivirus, adeno-associated virus (AAV) and adenoviral vectors
• Progress towards multi-vector multi-site model with transfer of lentiviral vector capabilities to Bedford, Massachusetts site and acquisition of ABL Europe
• Recruitment of UK and US Site Heads with extensive CDMO experience to support move to site-based structure and strategic shift to a pure-play CDMO
• Significant progress in streamlining of operations to become a pure-play CDMO resulting in annualised cost-savings of c.£30 million

https://www.biospace.com/article/releases/oxford-biomedica-business-update/